Clinical trials · New York, NY
Lung cancer clinical trials in New York
We’re tracking 285 recruiting lung cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT07783477RecruitingPhase 1
Armored CAR T cells for DLL3 positive cancers
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
New York, New YorkAges 18 years+ - NCT03808337RecruitingPhase 2
SBRT radiation plus standard treatment for spread cancer
This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.
New York, New YorkAges 18 years+ - NCT07246863RecruitingPhase 2
Testing visugromab and nivolumab with or without docetaxel for advanced lung cancer
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
New York, New YorkAges 18 years+ - NCT06033248Recruiting
Urine test for early lung cancer detection
This study is testing if urine samples can help detect lung cancer early. You might help by providing a urine sample—either if you have early-stage lung cancer, have a suspicious lung nodule, or don’t have lung cancer at all.
New York, New YorkAges 18–90 - NCT05424029Recruiting
Test blood and lung fluid markers to predict lung cancer return
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
New York, New YorkAges 18 years+ - NCT07218601RecruitingPhase 2
Using breath testing to track lung cancer treatment
This trial uses a special breath test (E-Nose) to monitor how well treatment is working in people with non-small cell lung cancer. You just breathe into a device, and it measures compounds in your breath.
New York, New YorkAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT06046495RecruitingPhase 1
Study of an oral EGFR inhibitor for non-small cell lung cancer
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
New York, New YorkAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
New York, New YorkAges 18 years+ - NCT06717243Recruiting
Study on gene markers in lung cancer for treatment resistance
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
New York, New YorkAges 18–85 - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
New York, New YorkAges 18–75 - NCT00301119Recruiting
Lung cancer screening using risk factors and test results
This study looks at how to find lung cancer earlier by screening people based on their lung-cancer risk. It may help doctors decide who needs further testing if lung nodules are found.
New York, New YorkAges 50 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
New York, New YorkAges 18 years+ - NCT06825715Recruiting
Precision oncology support for lung and prostate cancer
This study tests a program to help veterans with lung or prostate cancer get personalized cancer treatments. The goal is to see if extra support for doctors and patients leads to better use of precision medicine.
New York, New YorkAges Any age - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
New York, New YorkAges 18 years+ - NCT06079970Recruiting
Testing a microscope during lung biopsy
This trial tests if a special microscope (confocal laser endomicroscopy) used during a bronchoscopy can help doctors see and diagnose suspicious lung spots more clearly. It may help you if you have a small-to-medium sized spot in your lung that needs a biopsy.
New York, New YorkAges 18 years+ - NCT05058651RecruitingPhase 2/Phase 3
Atezolizumab plus chemo for advanced neuroendocrine cancer outside the lung
This trial tests whether adding an immunotherapy drug called atezolizumab to standard chemotherapy helps people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) that started outside the lung. The goal is to see if the combination works better than chemo alone.
New York, New YorkAges 18 years+ - NCT07128199RecruitingPhase 3
Zipalertinib after surgery for early-stage lung cancer with uncommon EGFR mutations
This study tests whether taking zipalertinib after lung cancer surgery can help prevent the cancer from coming back in people whose tumors have uncommon EGFR gene changes. It is a pill taken daily after recovery from surgery.
New York, New YorkAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
Engineered immune cells for advanced melanoma or lung cancer
This trial tests a new treatment called OBX-115, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments.
New York, New YorkAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
New York, New YorkAges 18 years+ - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT04165798Recruiting
Pembrolizumab with or without chemotherapy for stage IV lung cancer
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
New York, New YorkAges 18 years+ - NCT07037758RecruitingPhase 1
Study of tarlatamab and AB248 for extensive stage small cell lung cancer
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
New York, New YorkAges 18–90
Hear when a new Lung cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Lung cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting lung cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 12 studies
- Memorial Sloan Kettering Basking Ridge · 6 studies
- Memorial Sloan Kettering Bergen · 6 studies
- Memorial Sloan Kettering Monmouth · 6 studies
- Memorial Sloan Kettering Nassau · 5 studies
- Memorial Sloan Kettering Westchester · 5 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- NYU Langone Health · 2 studies
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lung cancer studies in New York.
Common questions
- Are there lung cancer clinical trials near New York?
- Yes. We're currently tracking 285 recruiting lung cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.